The adjuvant chemotherapeutic regimen of BV-CHP was selected over conventional CHOP based on the strong and diffuse CD30 expression in the neoplastic cells, the patient's young age and good performance status, and emerging evidence from the ECHELON-2 trial demonstrating superior progression-free survival with this regimen in CD30-positive peripheral T-cell lymphomas. Here, TNFRSF8 is linked to peripheral T-cell lymphoma, not otherwise specified.